Highlights from SABCS24 by Paolo Tarantino
The San Antonio Breast Cancer Symposium (SABCS) 2024 took place from December 10-13 in San Antonio, Texas.
The symposium will feature a comprehensive scientific program, including formal lectures by experts, selected slide and poster presentations, and case discussions focused on experimental biology, prevention, diagnosis, and therapy. With an emphasis on clinical, translational, and basic research, SABCS 2024 aims to foster collaboration and knowledge-sharing among academic and private physicians in oncology, as well as patient advocates and other healthcare professionals. The event will be conducted in English, with no simultaneous translation provided, and offers both in-person and virtual participation opportunities.
Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared his highlights from the conference:
How should we treat patients progressing on T-DXd?
“Wonderful to see multiple international efforts trying to answer a CRITICAL question: how should we treat patients progressing on T-DXd? Don’t miss this poster by great researcher and friend Kazuki Nozawa, reporting data on post-TDXd outcomes for 664 patients with HER2+ MBC.”
Intriguing results from the neoHIP randomized phase 2 trial
“Intriguing results from the neoHIP randomized phase 2 trial presented by Heather McArthur. The addition of pembro to neoadjuvant THP for stage II-III HER2+ BC improved pCR rate (delta 18%) with no new safety signals. Looking forward to seeing the impact of these results on EFS.”
The BR004 phase 3, closed early for safety concerns, shows no improvement in PFS
“Bad day for atezo. The BR004 phase 3, closed early for safety concerns, shows no improvement in PFS and higher number of toxicity-related deaths (6% vs 0% G5) with the addition of atezolizumab to 1L THP for HER2+ MBC.”
No improvement in DFS with adjuvant nivo/ipi (vs capecitabine) for TNBC with RD
“No improvement in DFS with adjuvant nivo/ipi (vs capecitabine) for TNBC with RD (RCB II-III). 3y DFS 62% vs 60%. More discontinuations and serious adverse events with nivo/ipi. Trial discontinued after 4 myocarditis events. No role for this adjuvant combo in breast oncology.”
Erica Mayer presents data from the ER+ arm of TBCRC056
“Erica Mayer presents data from the ER+ arm of TBCRC056. Among 18 gBRCA mut patients with stage I-IIA ER+ BC, neoadjuvant niraparib + dostarlimab achieved a pCR of 16.7%, RCB0/1 44% and numerical increase in TILs. Favorable tox profile.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023